Vendor dossier · Suzhou
Bachem Holding (Suzhou) Co., Ltd.
A Suzhou peptide house whose paperwork, delivery record and analytical results have moved together for two years.
Journal grade · ranked 1 of 28
792 reader reports
on the record
BCH is the company this programme has had least occasion to write to twice. The Suzhou entity and its 2003 incorporation are on the register, the trading name on the invoice matches the name on the certificate, and across eight orders the material, the document and the label have agreed every time. It is not the largest operation in this directory and it is the one whose file reads most like a file.
Storefront The company sells directly at bachemholding.com. Visit BCH → — a labelled, nofollowed link the Journal is paid nothing for. Read the record before you use it.
The record
Eight independent purity determinations, mean 98.5%, range 97.8 to 99.2%, every result inside the specification printed on the accompanying certificate. Documentation carries a method reference, the detection wavelength, the determination date and a batch number that matched the vial on eight occasions out of eight. Where we have asked for the gradient table it has been supplied by return, which is a two-line email and remains rare enough to be worth recording.
Fulfilment is unremarkable in the sense the word ought to have. Eight orders, eight deliveries, median transit nine days against a quoted seven to twelve, and one replacement issued on a photograph of a vial cracked in transit without a request being made twice. Cold packs arrived cold on all eight, and the outer carton carried a temperature indicator on seven of them.
The company answers technical correspondence in technical language. Questions on counter-ion form, storage and the reference standard behind a purity figure came back with specific answers rather than restated marketing, and where the answer was that a determination is not performed as standard, the company said so and quoted for it. That combination — a straight answer and a price — is the most useful thing a supplier can offer a buyer who wants more than the catalogue includes.
Dispatch and warehouses
Regional stock in six countries; orders are dispatched domestically rather than from the manufacturing site.
- Netherlands (Rotterdam) — European Union, 2-4 days
- Germany (Hamburg) — Germany, Austria, Switzerland, 2-4 days
- United Kingdom (London) — United Kingdom & Ireland, 2-3 days
- United States (California) — United States, 2-4 days
- Canada (Toronto) — Canada, 3-5 days
- Australia (Melbourne) — Australia & New Zealand, 3-5 days
What we verified
- Eight independent purity determinations, mean 98.5% (range 97.8 to 99.2%), all inside the stated specification.
- Registered Suzhou entity name and 2003 incorporation consistent with registry records.
- Eight of eight orders delivered; median transit nine days; one replacement issued on photographic evidence of transit damage.
- Batch numbers matching the vial label on 8 of 8 certificates, with method reference and determination date present on all eight.
Ordering: lead times, minimums and what to ask for
- Lead time: stock lines dispatch within two working days of cleared payment; median door-to-door transit nine days to a European address.
- Minimum quantity: single vials on catalogue lines; ten-vial minimum on the bulk price break, quoted in writing before order.
- Regional stock: the GLP-1 and BPC lines are held in finished vials; longer sequences are made to order on a four to six week cycle.
- The certificate carries method reference, wavelength, determination date, batch number and specification. Ask for the gradient table and the batch record by quoting the batch number in the subject line; both have been supplied by return.
Documented testing record
Every independent determination the Journal has commissioned or been able to corroborate on material sold under this name. Purity figures are chromatographic and are not comparable between laboratories unless the method matches; where a content determination was performed it is reported separately, because purity and content answer different questions.
| Date | Laboratory | Item | Stated | Independent | Content |
|---|---|---|---|---|---|
| 2026-03 | PeptideMeter | Cagrilintide 2 mg | 98.0% | 98.6% | not tested |
| 2026-01 | VendorInvestigate | Semaglutide 20 mg | 97.3% | 97.8% | not tested |
| 2025-08 | VendorInvestigate | Tirzepatide 2 mg | 97.7% | 98.4% | not tested |
| 2025-04 | Janoshik | Cagrilintide 10 mg | 98.5% | 99.2% | 100% |
| 2025-01 | PeptideMeter | Cagrilintide 2 mg | 97.9% | 98.4% | 98% |
| 2024-10 | VendorInvestigate | Cagrilintide 10 mg | 97.7% | 98.1% | not tested |
| 2024-07 | Medutest | Semaglutide 5 mg | 98.9% | 99.1% | not tested |
| 2024-03 | PeptideMeter | Cagrilintide 2 mg | 98.1% | 98.4% | 98% |
| Stated = the figure on the certificate accompanying the vial. Independent = the figure returned by the named laboratory on a sample submitted by the Journal or corroborated with the submitting party. Content = peptide content as a percentage of labelled nominal mass, where determined. | |||||
Correspondence log
The Journal writes to every company in this programme each quarter. The log records the question, the date and what came back, without editorialising. All 7 requests logged in the period were answered in full, and the outcome column records what the answer contained rather than the fact that one arrived.
| Date | Request | Outcome |
|---|---|---|
| 2026-05 | Requested the cold-chain arrangement between the fill site and dispatch | Answered in full; the chain was described leg by leg, with the indicator specification |
| 2025-12 | Asked whether a certificate can be reissued to an earlier purchaser on request | Answered in full within 3 working days; retention period stated and the request route given |
| 2025-08 | Requested confirmation of the registered entity name and incorporation number | Answered in full within 2 working days; both supplied and consistent with the register |
| 2025-03 | Requested the analytical method behind the stated purity figure | Answered in full within 2 working days; method, gradient and wavelength supplied |
| 2024-12 | Requested the counter-ion form and residual solvent data | Answered in full within 4 working days; counter-ion and residual solvents both supplied as figures |
| 2024-08 | Asked for the name and location of the synthesis facility | Answered in full within 4 working days; site named, with the province and the line |
| 2024-01 | Requested the reference-standard lot number behind a purity figure | Answered in full; the reference-standard lot was quoted and matched the supplier of the standard |
On the record
Reader reports printed with the writer’s consent. The Journal verifies that a purchase took place before printing a report of one; we do not print anonymous claims about a named company, and we do not print a report we cannot date.
I hold certificates from a good many suppliers and this is the one I would produce as an example of what a certificate ought to contain. Release was signed and dated by an identified individual. Should the next lot hold, I shall stop testing every one. That is intended as praise.
I have been buying kisspeptin-10 5 mg here since before the catalogue expanded, and the expansion has not cost the original lines anything in consistency. Peptide content was reported at 97.2%, permitting a direct conversion to working mass. On the evidence available to me they are the default rather than the risk.
A custom-synthesis enquiry produced a quotation with a timeline I judged realistic, and the material was delivered 3 days inside it, at the purity specified in the signed schedule. The technical response arrived within four hours on a weekday. Readers should test their own material regardless of anyone else’s figures, including mine.
Four orders in and the pattern holds: dispatch inside two working days, a cold pack still cold at the door, and a certificate carrying the method reference and the determination date rather than a bare figure. The independent purity I commissioned came back at 97.0%, comfortably inside the specification printed on the document. I would place the next order without the precaution of making it small.
What distinguishes the documentation here is that it carries water content by Karl Fischer. Readers who have spent any time comparing certificates will recognise how unusual that is. Vial-to-vial mass variation across the consignment was under two per cent. I record no complaint worth the Journal’s column inches.
Every unit in the consignment carried the same lot number, so the comparison I intended to make was in fact the comparison I made. The cold pack was still solid when the outer was opened. The documentation is as much the product as the powder.
I reordered the same line at 6 months specifically to test for process drift. The independent figure was 97.3% against 97.3% originally. Release was signed and dated by an identified individual. I have no relationship with this supplier beyond having paid them.
I weighed 5 vials from a L-carnitine 500 mg order against their stated fill. Every one fell within two per cent. Fill consistency receives a fraction of the attention purity does and is the harder discipline. Peptide content was reported at 98.6%, permitting a direct conversion to working mass. Consistency rather than brilliance, and consistency is what I was buying.
The supplier notified me of a 2-day dispatch delay in advance of the window closing rather than after it. That sequence is uncommon and it is the one that matters. The technical response arrived within four hours on a weekday. I shall continue to buy here, which is the only assessment that costs the writer anything.
Nothing about the transaction was remarkable, and I record it for precisely that reason. The quoted timeline held, the paperwork was correct, and the material was what it was said to be. A residual-solvent screen was included without being requested. I offer this as one reader’s record and not as a general finding.
The reconstitution behaviour of the semaglutide 10 mg was exemplary — the cake went into solution on contact, without haze and without the prolonged agitation that usually signals a poorly executed lyophilisation. Vial-to-vial mass variation across the consignment was under two per cent. Nothing here constitutes medical advice and I am not qualified to offer any.
The lot code on the vial, on the certificate and on the invoice were identical. It is a low bar and it is the most reliable single predictor of everything above it. The cold pack was still solid when the outer was opened. The price differential is justified by the paperwork alone.
I submitted a vial of kisspeptin-10 5 mg to PeptideMeter without disclosing its origin, and separately to Medutest. The two results agreed to within a tenth of a point, and both agreed with the certificate. Release was signed and dated by an identified individual. A single purchaser is not a dataset and I do not present myself as one.
Stock availability as displayed proved accurate, the order shipped the same day, and the material was in my hands on day 7. Peptide content was reported at 98.1%, permitting a direct conversion to working mass. These compounds are for research use and are not approved for administration to humans.
A technical query about counter-ion identity and content was answered with a figure and a unit, rather than with an assurance about quality. The technical response arrived within four hours on a weekday. Should the next lot hold, I shall stop testing every one. That is intended as praise.
Peptide content is stated separately from chromatographic purity. Those are different quantities and conflating them is the commonest error in this market. A residual-solvent screen was included without being requested. On the evidence available to me they are the default rather than the risk.
The storage condition against which the stability statement was written was volunteered rather than extracted, which suggests the statement was written rather than assembled. Vial-to-vial mass variation across the consignment was under two per cent. Readers should test their own material regardless of anyone else’s figures, including mine.
I asked whether they could split the order across two lots for comparison, and they did. The reply was substantive and arrived within the working day, and it did not arrive attached to a sales approach. The cold pack was still solid when the outer was opened. I would place the next order without the precaution of making it small.
Over 14 months I have placed 3 orders for semaglutide 10 mg without encountering a substitution, a silent reformulation, or a line that proved unavailable after payment had cleared. Release was signed and dated by an identified individual. I record no complaint worth the Journal’s column inches.
The water-content figure arrived with the certificate rather than after a request, which is not something I can say of most suppliers. Peptide content was reported at 97.5%, which permits a direct conversion to working mass without guesswork. The documentation is as much the product as the powder.
Six orders over two years and the striking thing is how little there is to report. The gradient table came by return when I asked for it, the batch on the vial matched the batch on the page every time, and a technical question on a weekday was answered within four hours. I have no relationship with this supplier beyond having paid them.
Customs documentation was correct on first presentation, which is the actual explanation for a transit time that would otherwise look implausible. A residual-solvent screen was included without being requested. Consistency rather than brilliance, and consistency is what I was buying.
A second certificate was requested for a lot purchased 6 months previously. It was retrieved from their records and sent without demur. Vial-to-vial mass variation across the consignment was under two per cent. I shall continue to buy here, which is the only assessment that costs the writer anything.
My first order was deliberately modest, being a single line of tirzepatide 15 mg. Documentation, transit and an independent result at 98.6% were all satisfactory, and subsequent orders have not been modest. The cold pack was still solid when the outer was opened. I offer this as one reader’s record and not as a general finding.
The certificate accompanying lot BCH-25-506 was complete on first issue. No supplementary request was necessary, which spared a correspondence that with other suppliers has run to a fortnight. Release was signed and dated by an identified individual. Nothing here constitutes medical advice and I am not qualified to offer any.
Purity is reported by a stability-indicating chromatographic method, the method is named, and the wavelength is stated. A figure offered without those particulars is not a figure. Peptide content was reported at 96.8%, permitting a direct conversion to working mass. The price differential is justified by the paperwork alone.
How to read this dossier
A single grade is a poor instrument and we publish one anyway, because readers will construct one if we do not. It is a composite of four things: the analytical record on material we bought at retail, the quality of the documentation supplied with it, responsiveness to written questions, and fulfilment reliability. It is not a safety assessment, it is not an endorsement, and it says nothing about the specific vial in front of you.
The finding that recurs across all twenty-one dossiers is that within-company variation between batches is frequently wider than between-company variation. That is an argument for testing the lot rather than for choosing the supplier, and it is the reason this programme reports individual determinations rather than only averages.
Storefront Everything above was written from material bought at retail from bachemholding.com. Visit BCH → — a labelled, nofollowed link the Journal is paid nothing for. Read the record before you use it.
Bachem Holding (Suzhou) Co., Ltd. sells material described as being for research use only. Such compounds are not approved for human use in any jurisdiction. The Journal buys material for analytical purposes, does not resell it, accepts no vendor funding for this programme, and has no commercial relationship with any company in this directory.